CHARLOTTE, N.C., May 22, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 38th Annual Deutsche Bank Health Care Conference at 4:50 PM on Wednesday, May 29, 2013 in Boston.
Nick Riehle, Vice President Administration and Chief Financial Officer will provide a corporate update and an ov...
CHARLOTTE, N.C., May 1, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the first quarter ended March 31, 2013.
"In the first quarter, we made significant progress toward the commercialization of Northera™ (droxidopa) for the treatment of symptomatic Neurogenic Orthostat...
CHARLOTTE, N.C., April 24, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present the 12th Annual Needham Healthcare Conference at 10:40 AM on Wednesday, May 1, in New York.
Joseph G. Oliveto, Chelsea's Interim Chief Executive Officer will provide a corporate update and an overview of the Norther...
CHARLOTTE, N.C., March 19, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that Dr. Stuart Isaacson, Clinical Associate Professor, Department of Neurology, Herbert Wertheim College of Medicine, Florida International University, will present results from Northera™ (droxidopa) Study 306 at the Ame...
CHARLOTTE, N.C., March 12, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 25TH Annual ROTH Conference at 3:30 PM PT on Tuesday, March 19, 2013 in Dana Point, CA.
Joseph G. Oliveto, Chelsea's Interim Chief Executive Officer will provide a corporate update and an overview of the Nort...
CHARLOTTE, N.C., March 7, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year ended December 31, 2012.Fourth Quarter and Recent Highlights
In February 2013, Chelsea received written guidance from the Director of the Office of New Drugs at the U.S....
Company to Resubmit NDA in Late Second Quarter 2013Short-term Clinical Benefit Adequate to Support ApprovalCompany to Host Conference Call Today at 9:00 AM ET
CHARLOTTE, N.C., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that it has received written guidance from the Director of the Of...
Northera™ Demonstrated Statistically Significant Improvement Over Placebo in Reduction of Dizziness/Lightheadedness at Week 1 (p=0.018), the Primary Endpoint, and Standing Blood Pressure at Week 1 (p=0.032), a Key Secondary EndpointNorthera Patients Experienced Fewer Falls and Fall-related Injuries, Although Results Were Not Statistically Sig...
CHARLOTTE, N.C., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the quarter and nine months ended September 30, 2012.
"As 2012 draws to a close, we look forward to reporting results, in the fourth quarter, from Northera Study 306B, the largest clinical trial ever cond...
CHARLOTTE, N.C., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced results from a study of Northera™ (droxidopa) in hypotensive individuals with spinal cord injury at the 23rd International Symposium on the Autonomic Nervous System, which took place October 31 through November 3, 2012 in P...
CHARLOTTE, N.C., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 14th Annual Rodman & Renshaw Global Healthcare Investment Conference at 3:40 PM ET on Monday, September 10, 2012 at the Waldorf Astoria in New York City.
Joseph G. Oliveto, Chelsea's Interim Chief Executive Of...
CHARLOTTE, N.C., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference at 2:30 PM ET on Tuesday, August 14, 2012 at the Le Parker Meridien Hotel in New York City.
Joseph G. Oliveto, Chelsea's Interim Chief Executive O...
CHARLOTTE, N.C., Aug. 7, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the quarter and six months ended June 30, 2012.
For the quarter ended June 30, 2012, Chelsea reported a net loss of $7.9 million or ($0.12) per share versus a net loss of $13.3 million or ($0.21) per shar...
CHARLOTTE, N.C., July 10, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that its Board of Directors plans to promptly implement a corporate reorganization that includes a reduction in force, executive changes and changes to the Company's Board of Directors, and has authorized a plan to explore and e...
CHARLOTTE, N.C., July 3, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) received a written response from the U.S. Food and Drug Administration (FDA) to Chelsea's modified proposal for utilizing data from ongoing Study 306B to support its application for marketing approval of Northera™ (droxidopa) in the U.S. I...
CHARLOTTE, N.C., June 21, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced results from an integrated dataset of two phase 3 studies, Study 301 and Study 302, which showed that patients treated with Northera™ (droxidopa) experienced improvements in their symptoms of Neurogenic Orthostatic Hypoten...
Officers and Directors Agree to 25% Reduction in Compensation
Approximately 35% of Remaining Employees to Transition to Part-Time Status
Chelsea Eliminating All Performance Bonuses Until U.S. Approval of Northera™ (droxidopa)
Company planning to transition patients from ongoing safety study to more cost-effective access program...
CHARLOTTE, N.C., May 31, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that a preliminary analysis of its dose-ranging exploratory Phase II trial of CH-4051, a non-metabolized antifolate, in patients with rheumatoid arthritis (RA) who experience an inadequate response to methotrexate (MTX) treatment indic...
Chelsea Proposing to Change Primary Endpoint and Submit Dizziness Data From Ongoing Study 306B to Support Resubmission of Northera NDA for the Treatment of Symptomatic Neurogenic Orthostatic HypotensionCompany to Host Conference Call at 8:30 AM ET
CHARLOTTE, N.C., May 22, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq...
In a press release issued earlier today by Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), please note the last sentence of the sixth paragraph should have read: Chelsea anticipates that available cash and cash equivalents should fund the company's operating plans into the second quarter of 2013. The full, corrected release follows:Chelsea ...
Delicious
Digg
Facebook
LinkedIn
Twitter
